Oxybutynin Chloride Tablet, Extended Release
Product Images NDC 72789-049

7 FDA label images from Pd-rx Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 72789-049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

72789049 Label (72789049)

72789049 Label (72789049)
Label for oxybutynin chloride extended-release tablets, 10 mg strength, containing 90 tablets per bottle. The label shows the product NDC 72789-049-90 and is packaged by PD-Rx Pharmaceuticals, Inc. in Oklahoma City, OK. The label includes dosage, storage warnings, and reorder, lot, and expiration information (exp 08/2021).*
FDA Label Image

Figure 1 (Oxybutynin Fig 1)

Figure 1 (Oxybutynin Fig 1)
A line graph comparing mean plasma R-Oxybutynin concentration (ng/mL) over 24 hours for oxybutynin ER 10 mg once daily (QD) versus oxybutynin 5 mg three times daily (TID). The x-axis represents time in hours, and the y-axis represents concentration with error bars indicating variability.*
FDA Label Image

Figure 2 (Oxybutynin Fig 2)

Figure 2 (Oxybutynin Fig 2)
A line graph showing mean R-oxybutynin plasma concentration (ng/mL) plotted against time (hours). The graph depicts concentration values from 0 to 24 hours, with error bars indicating variability at each time point.*
FDA Label Image

Figure 3 (Oxybutynin Fig Study 1)

Figure 3 (Oxybutynin Fig Study 1)
A horizontal bar chart comparing the mean change in episodes per week from baseline between oxybutynin ER and placebo. The x-axis ranges from -40 to 40, showing the mean change with error bars for standard deviation for both groups.*
FDA Label Image

Figure 4 (Oxybutynin Fig Study 2)

Figure 4 (Oxybutynin Fig Study 2)
A horizontal bar chart comparing the mean change (±SD) in episodes per week from baseline for oxybutynin ER and oxybutynin. The x-axis is labeled with values from -40 to 40 and titled 'Mean Change (±SD) in Episodes Per Week from Baseline.'*
FDA Label Image

Figure 5 (Oxybutynin Fig Study 3)

Figure 5 (Oxybutynin Fig Study 3)
A bar chart illustrating the mean change (± standard deviation) in episodes per week from baseline for oxybutynin extended release and oxybutynin. The horizontal axis ranges from -40 to 40, showing change in episodes per week, with both treatments showing negative mean changes.*
FDA Label Image

Chemical Structure (Oxybutynin Struc)

Chemical Structure (Oxybutynin Struc)
Chemical structure diagram of oxybutynin chloride, illustrating the molecular arrangement of atoms and bonds in the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.